title: The role of PET/CT as a prognosticator and outcome predictor in lung cancer.
abstract: Positron emission tomography/computed tomography (PET/CT) is an important imaging tool for management of lung cancer and can be utilized in diagnosis, staging, restaging, treatment planning and evaluating treatment response. In the past decade PET/CT has proven to be beneficial for the prediction of prognosis and outcome. PET findings before and after treatment, the quantitative PET parameters such as standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) as well as delayed PET/CT imaging can be used to determine patient prognosis and outcome. Other tracers such as hypoxia and proliferation marker tracers may be used for prognostication. The prognostic factors derived from PET/CT imaging help early development of risk-adapted treatment strategies, which provides cost-effective treatment and leads to improved patient management. Here, we discuss findings of studies related to application of PET/CT in lung cancer as well as some technical updates on quantitative PET/CT in lung cancer.
authors.affiliation: a Department of Radiology, Hospital of the University of Pennsylvania , Philadelphia , PA , USA.
authors.forename: Benjapa
authors.initials: B
authors.lastname: Khiewvan
authors.affiliation: b Department of Radiology , Mercy Catholic Medical Center , Philadelphia , PA , USA.
authors.forename: Pouya
authors.initials: P
authors.lastname: Ziai
authors.affiliation: a Department of Radiology, Hospital of the University of Pennsylvania , Philadelphia , PA , USA.
authors.forename: Sina
authors.initials: S
authors.lastname: Houshmand
authors.affiliation: a Department of Radiology, Hospital of the University of Pennsylvania , Philadelphia , PA , USA.
authors.forename: Ali
authors.initials: A
authors.lastname: Salavati
authors.affiliation: a Department of Radiology, Hospital of the University of Pennsylvania , Philadelphia , PA , USA.
authors.forename: Peyman
authors.initials: P
authors.lastname: Ziai
authors.affiliation: a Department of Radiology, Hospital of the University of Pennsylvania , Philadelphia , PA , USA.
authors.forename: Abass
authors.initials: A
authors.lastname: Alavi
mesh_terms: D003287:Contrast Media; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy; D009367:Neoplasm Staging; D000072078:Positron Emission Tomography Computed Tomography; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D019275:Radiopharmaceuticals; D012307:Risk Factors; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D003287:Contrast Media; D019275:Radiopharmaceuticals
keywords: FDG-PET/CT; Lung cancer; PET/MRI; delayed time point imaging; metabolic tumor volume; total lesion glycolysis